$GRAIL(GRAL.US) | Goldman Sachs 𝐢𝐧𝐢𝐭𝐢𝐚𝐭𝐞𝐬 𝐜𝐨𝐯𝐞𝐫𝐚𝐠𝐞 on 𝐆𝐑𝐀𝐈𝐋 with a 𝐍𝐞𝐮𝐭𝐫𝐚𝐥 rating and a 𝐩𝐫𝐢𝐜𝐞 𝐭𝐚𝐫𝐠𝐞𝐭 𝐨𝐟 $𝟔𝟎
Analyst sees GRAL's path to profitability hinging on uncertain FDA approval and CMS coverage for its Galleri multi-cancer early detection test.
Share your thoughtsWhat's on your mind?
0 / 2,000